India's Cadila Healthcare Receives FDA Warning Letter

Jan 05, 2016

The Telegraph

Cadila Healthcare has received a warning letter from the U.S. Food and Drug Administration for two facilities in Gujarat, India, according to an article in The Telegraph.

The company said it had received an FDA warning letter targeting its formulation facility at Moraiya and an active pharmaceutical ingredient unit (Zyfine) in Ahmedabad. Cadila said there were no products in the United States that used API from the Zyfine facility.

Read the full story

View the most popular news stories in 2015 from Pharmaceutical Manufacturing.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments